Bristol Myers Squibb has signed a deal worth up to 15.2 billion dollars with Jiangsu Hengrui Medicine, China’s largest pharmaceutical company by market capitalisation. The agreement covers 13 early-stage drug programmes across oncology, haematology, and immunology. None of the drugs have entered human clinical trials. The deal was announced on the same day that […]<br /> This story continues at The Next Web [...]
For more than three decades, modern CPUs have relied on speculative execution to keep pipelines full. When it emerged in the 1990s, speculation was hailed as a breakthrough — just as pipelining and [...]
Content creation is one of the biggest struggles for many marketers and business owners. It often requires both time and financial resources, especially if you plan to hire a writer.Today, we have a f [...]